| Identification of a novel GPR81-selective agonist that suppresses lipolysis in mice without cutaneous flushing T Sakurai, R Davenport, S Stafford, J Grosse, K Ogawa, J Cameron, ... European journal of pharmacology 727, 1-7, 2014 | 53 | 2014 |
| 1,2,4-Triazolo-[1,5-a]pyridine HIF Prolylhydroxylase Domain-1 (PHD-1) Inhibitors With a Novel Monodentate Binding Interaction S Ahmed, A Ayscough, GR Barker, HE Canning, R Davenport, ... Journal of Medicinal Chemistry 60 (13), 5663-5672, 2017 | 32 | 2017 |
| 2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists DA Sandham, C Aldcroft, U Baettig, L Barker, D Beer, G Bhalay, Z Brown, ... Bioorganic & medicinal chemistry letters 17 (15), 4347-4350, 2007 | 22 | 2007 |
| Discovery of a series of ester-substituted NLRP3 inflammasome inhibitors D Harrison, N Boutard, K Brzozka, M Bugaj, S Chmielewski, A Cierpich, ... Bioorganic & Medicinal Chemistry Letters 30 (23), 127560, 2020 | 21 | 2020 |
| Discovery and optimization of triazolopyrimidinone derivatives as selective NLRP3 inflammasome inhibitors D Harrison, MG Bock, JR Doedens, CA Gabel, MK Holloway, A Lewis, ... ACS Medicinal Chemistry Letters 13 (8), 1321-1328, 2022 | 12 | 2022 |
| Discovery of clinical candidate NT-0796, a brain-penetrant and highly potent NLRP3 inflammasome inhibitor for neuroinflammatory disorders D Harrison, A Billinton, MG Bock, JR Doedens, CA Gabel, MK Holloway, ... Journal of Medicinal Chemistry 66 (21), 14897-14911, 2023 | 8 | 2023 |
| 4-carboxypyrazole derivatives as anti-viral agents G Bravi, A Cheasty, J Corfield, R Grimes, D Harrison, C Hartley, P Howes, ... WO Patent WO2,007,039,146, 2007 | 7 | 2007 |
| Antiviral 2-Carboxy-Thiophene Compounds JA Corfield, RM Grimes, D Harrison, CD Hartley, PD Howes, J Le, ... US Patent App. 12/097,840, 2009 | 5 | 2009 |
| Reversal of High Fat Diet-Induced Obesity, Systemic Inflammation, and Astrogliosis by the NLRP3 Inflammasome Inhibitors NT-0249 and NT-0796 P Thornton, V Reader, Z Digby, P Smolak, N Lindsay, D Harrison, ... Journal of Pharmacology and Experimental Therapeutics 388 (3), 813-826, 2024 | 2 | 2024 |
| Sulphonyl urea derivatives as NLRP3 inflammasome modulators D Harrison, AP Watt, MG Bock US Patent 11,518,757, 2022 | 2 | 2022 |
| Selective inhibitors of nlrp3 inflammasome MG Bock, AP Watt, RA Porter, D Harrison, NFP Boutard, GW TOPOLNICKI, ... | 2 | 2020 |
| Target cell activation of a structurally novel NLRP3 inhibitor NT-0796 enhances potency P Smolak, MT Nguyen, C Diamond, H Wescott, JR Doedens, K Schooley, ... Journal of Pharmacology and Experimental Therapeutics, 2024 | 1 | 2024 |
| Pharmacological Analysis of NLRP3 Inflammasome Inhibitor Sodium [(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl][(1-methyl-1H-pyrazol-4-yl)({[(2S)-oxolan … JR Doedens, P Smolak, MT Nguyen, H Wescott, C Diamond, K Schooley, ... ACS Pharmacology & Translational Science, 2024 | | 2024 |
| Target Cell Activation of a Structurally Novel NOD-Like Receptor Pyrin Domain-Containing Protein 3 Inhibitor NT-0796 Enhances Potency P Smolak, MT Nguyen, C Diamond, H Wescott, JR Doedens, K Schooley, ... Journal of Pharmacology and Experimental Therapeutics 388 (3), 798-812, 2024 | | 2024 |
| Selektivni inhibitori nlrp3 inflamazoma MG Bock, AP Watt, RA Porter, D Harrison, NFP Boutard, GW Topolnicki, ... | | 2024 |
| Sulphamoyl urea derivatives containing alkyl-oxacycloalkyl moiety and uses thereof MG Bock, D Harrison, JE Scanlon US Patent App. 18/043,883, 2024 | | 2024 |
| Selektive hæmmere af nlrp3-inflammasom MG Bock, AP Watt, RA Porter, D Harrison, NFP Boutard, GW Topolnicki, ... | | 2024 |
| Selektiivisiä nlrp3-inflammasomin estäjiä MG Bock, AP Watt, RA Porter, D Harrison, NFP Boutard, GW Topolnicki, ... | | 2024 |
| Sulphonyl urea derivatives as nlrp3 inflammasome modulators D Harrison, AP Watt, MG Bock US Patent App. 17/967,599, 2023 | | 2023 |
| Sulfonylurea derivatives and uses thereof MG Bock, D Harrison, JE Scanlon US Patent App. 17/618,188, 2023 | | 2023 |
